Matching articles for "AirSupra"
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • November 25, 2024; (Issue 1716)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • November 25, 2024; (Issue 1716)
...
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • March 18, 2024; (Issue 1698)
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.